---
schema_version: "secwatch.filing_event.v1"
accession: "0000944809-23-000010"
form_type: "8-K"
ticker: "OPK"
cik: "0000944809"
company_name: "OPKO HEALTH, INC."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T03:54:10.326459+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# OPKO Health Q4 2022 revenue drops to $185.4M; net loss $85.2M

## Summary
- Consolidated revenue $185.4M vs $401.3M YoY; net loss $85.2M ($0.11/share) includes $49.1M non-cash charge on GeneDx investment.
- Diagnostics revenue $139.4M (down from $362.8M) due to COVID-19 testing decline; BioReference processed 0.1M PCR tests vs 2.7M.
- Pharmaceuticals revenue $37.9M (up from $35.3M) driven by RAYALDEE ($9.1M) and IP transfer ($8.1M); NGENLA sales underway in 15 countries.
- Operating loss $55.3M vs $63.1M; cash $153.2M as of Dec 31, 2022.
- BioReference implementing cost-cutting initiatives to return to profitability after COVID-19 testing decline.

## SEC filing metadata
- accession: 0000944809-23-000010
- form_type: 8-K
- ticker: OPK
- cik: 0000944809
- company_name: OPKO HEALTH, INC.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/944809/000094480923000010/0000944809-23-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/944809/000094480923000010/opk-20230223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000944809-23-000010
- JSON: https://secwatch.observer/filing/0000944809-23-000010.json
- Plain text: https://secwatch.observer/filing/0000944809-23-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.